G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing, because that oh-so-familiar routine of meetings, deadlines, and whatnot has returned. You knew this would happen, yes? To cope, we are turning to cups of stimulation and invite you to join us. Remember, no prescription is required. And as we have noted previously, this means you do not have to concern yourself with copays or understanding rebates. Meanwhile, here are some tidbits to get you going. Have a great day and do keep in touch …

Shire (SHPG) is selling its oncology business to unlisted French drug maker Servier for $2.4 billion, a deal that suggests there is value locked up within the Shire portfolio, despite a dismal share price performance in the past two years, Reuters explains. Meanwhile, Takeda Pharmaceuticals (TKPYY) chief executive Chrisophe Weber is reported to be lining up meetings with its major Shire investors ahead of making a potential $50 billion offer for Shire, the Telegraph says. The sale of the cancer business may be a deterrent for Takeda, since oncology is one area highlighted as driving the case for a deal.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.